BCL2L13

BCL2L13protein

BCL2L13 suppression by miR-96-5p promotes cardiomyocyte apoptosis during myocardial ischemia and infarction.

Pathway placement

Cascade stepMyocardial injury (shared endpoint)

Confidencemedium

RationaleAnti-apoptotic protein; miR-96-5p target regulating cardiomyocyte survival.

Druggability

DruggableYes

Known drugs / candidates0

Small-molecule tractableNo

Antibody tractableYes

EnsemblENSG00000099968

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma

Collection tube

Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)

Method / principle

Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists

Reagent / substrate

Matched anti-target antibody pair (capture + labeled detection)

Platform

ELISA microplate or multiplex (Luminex/MSD)

Turnaround · availability

Send-out / research · Research-grade (no universal clinical assay)